Status:
COMPLETED
Effects of Continuous Veno-venous Haemofiltration on Plasma Lactate in Critically Ill Patients
Lead Sponsor:
First Affiliated Hospital, Sun Yat-Sen University
Conditions:
Kidney Injury, Acute
Eligibility:
All Genders
18-75 years
Brief Summary
Continuous Veno-Venous Hemofiltration (CVVH) can eliminate metabolic products effectively and replace renal function partly. It is widely used in intensive care units (ICUs), especially for patients w...
Eligibility Criteria
Inclusion
- The critical ill patients with acute kidney injury
- Patients requiring continuous veno-venous hemofiltration
- APACHE II scores more than 12
- Arterial lactate is higher than 0.5mmol/L but lower than 15mmol/L (due to the sensitivity and optimal measuring range of the equipment)
- Continuous veno-venous hemofiltration for at least 12 hrs
- Hemo-filter age of \<24 hrs
Exclusion
- APACHE II scores lower than 12
- patients' age are more than 75Y or lower than 18Y
Key Trial Info
Start Date :
March 3 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 20 2015
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT01824771
Start Date
March 3 2013
End Date
March 20 2015
Last Update
July 27 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The first affiliated hospital, Sun Yat-sen University
Guangzhou, Guangdong, China, 510080